Date and Time: 11.00am – 5.30pm 27th November 2014
9.30am – 2.00pm 28th November 2014

Minutes: Confirmed

Guideline Development Group Meeting: Tuberculosis

Place: NICE offices, London

Present: Andrew Hayward (AH) (Chair)
Ibrahim Abubakar (IA) (Chair) (Day 2 only)
Sudy Anaraki (SA)
Al Story (AS)
Christine Bell (CB)
Timothy Collyns (TC)
Michael Eisenhut (ME)
Bertie Squire (BS)
Ann Chapman (AC)
Mango Hoto (MH) (Day 2 only)
Amy McConville (AM)
Francis Drobniewski (FD) (Day 1 only)
Horace Reid (HR) (Day 1-pm and Day 2 only)
Uday Katkar (UK)

Apologies: Francis Drobniewski (FD) (Day 2 only)
Ibrahim Abubakar (IA) (Day 1 only)
Horace Reid (HR) (Day 1-am)
Marc Lipman (ML)
Mango Hoto (Day 1 only)

In attendance:

NICE Staff:
Lucy Hoppe (LH)
Margaret Derry (MD)
Rachel Kettle (RK)
Hugh McGuire (HM) (Day 1 and part of Day 2)
Chris Gibbons (CG)
Gabriel Rogers (GR) (Day 1 only)
Ben Doak (BD) (Day 1 only)

Warwick Evidence Team:
Joshua Pink (JP) (Part of Day 1 only)
Peter Auguste (PA) (Part of Day 1 only)
1. AH welcomed all to the 16th TB GDG meeting. Apologies were noted and the minutes of the last meeting were agreed as an accurate record. The Chair provided a brief overview of the day highlighting the information that would be discussed.

2. All GDG members were asked to share any new conflicts of interest which have not previously been declared. No new conflicts of interest were declared by the group or the NICE team.

3. The team from Warwick Evidence presented the initial health economic results. The group discussed the emerging findings and assumptions and requested some further changes.

4. JB went through the review protocols, search strategies and included evidence used to inform the following questions:

   For people in hospital who have active TB, what infection control measures are the most effective in preventing transmission of TB infection to others?

   For people who have active TB who are not in hospital but are in congregate settings what infection control measures are the most effective in preventing transmission of TB infection to others?

   The GDG requested amendments to the protocols and recommended further studies for inclusion. These review questions will be re-presented at the next GDG meeting.

5. CG presented an outline of the health economics work for the following questions and sought GDG advise on the approach and outstanding queries:

   For people who have active TB that is not suspected to be MDR-TB, and for whom isolation is indicated, what factors should determine the duration of isolation necessary to minimise the risk of infection to others? What is the optimum duration?

   For people who have active TB that is suspected to be MDR-TB, and for whom isolation is indicated, what factors should determine the duration of isolation necessary to minimise the risk of infection to others? What is the optimum duration?

   The group discussed the approach, addressed questions and gave feedback.

6. No further business was discussed.

Notes: 28th November 2014

7. AH provided a recap of day 1 and IA outlined the objectives for day 2.

8. CG briefly went through a couple of outstanding economics queries from the previous day’s discussions and JB recapped the requested changes to the protocols for infection control.

9. LH presented the clinical reviews for the review question: For people receiving drug treatment for active TB who experience treatment interruptions, what approach to re-establishing appropriate treatment is the most effective in reducing mortality and morbidity?
LH went through the review protocols, search strategies and included evidence used to inform these questions. The GDG discussed the evidence available and updated the existing recommendations from CG117.

10. LH and MD took the GDG through the draft recommendations made over the 2 days and editing queries for recommendations made to date. The group discussed and addressed the queries, amending the recommendations where appropriate.

11. IA provided a summary of the day and thanked all for their attendance and input.

**Date, time and venue of the next meeting**
10:30am – 12\textsuperscript{th} and 13\textsuperscript{th} January at the NICE offices in Manchester.